kynurenine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 44 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Indoleamine 2,3 dioxygenase (Ido1), the first and rate-limiting enzyme of the kynurenine pathway (KP), is a striatally enriched gene with increased expression levels in the YAC128 mouse model of Huntington disease (HD)." | 7.79 | Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. ( Adomat, H; Budac, DP; Leavitt, BR; Lu, G; Mazarei, G; Möller, T; Tomlinson Guns, ES, 2013) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 7.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 6.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 6.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "Indoleamine 2,3 dioxygenase (Ido1), the first and rate-limiting enzyme of the kynurenine pathway (KP), is a striatally enriched gene with increased expression levels in the YAC128 mouse model of Huntington disease (HD)." | 3.79 | Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. ( Adomat, H; Budac, DP; Leavitt, BR; Lu, G; Mazarei, G; Möller, T; Tomlinson Guns, ES, 2013) |
| "The kynurenine pathway of tryptophan degradation is hypothesized to play an important role in Huntington disease, a neurodegenerative disorder caused by a polyglutamine expansion in the protein huntingtin." | 3.74 | Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. ( Cheah, CS; Giorgini, F; Guidetti, P; Hong, S; Kwan, W; Möller, T; Muchowski, PJ; Schwarcz, R; Tsai, LC; Wacker, JL; Zwilling, D, 2008) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 3.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations." | 2.66 | Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. ( Tanaka, M; Toldi, J; Vécsei, L, 2020) |
| " The toxic effects of 3-hydroxy-L-kynurenine are mediated by free radicals." | 2.48 | Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders. ( Fülöp, F; Klivényi, P; Szalárdy, L; Toldi, J; Vécsei, L; Zádori, D, 2012) |
| "The neurodegenerative disease Huntington's disease (HD) is caused by an expanded polyglutamine (polyQ) tract in the protein huntingtin (htt)." | 2.46 | Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. ( Guidetti, P; Muchowski, PJ; Sathyasaikumar, KV; Schwarcz, R, 2010) |
| "Quinolinic acid is an agonist at the population of glutamate receptors which are sensitive to N-methyl-D-aspartate (NMDA), and kynurenic acid is an antagonist at several glutamate receptors." | 2.42 | Tryptophan metabolites and brain disorders. ( Clark, CJ; Darlington, LG; Forrest, CM; Mackay, GM; Stone, TW, 2003) |
| "3-Hydroxykynurenine was substantially and significantly increased in all three brain areas studied in Huntington's disease, but not significantly increased in the cortex in Alzheimer's disease, when compared to matched controls." | 1.28 | Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. ( Pearson, SJ; Reynolds, GP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.27) | 18.7374 |
| 1990's | 10 (22.73) | 18.2507 |
| 2000's | 9 (20.45) | 29.6817 |
| 2010's | 17 (38.64) | 24.3611 |
| 2020's | 7 (15.91) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Bains, M | 1 |
| Kaur, J | 1 |
| Akhtar, A | 1 |
| Kuhad, A | 1 |
| Sah, SP | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Shen, H | 1 |
| Xu, X | 1 |
| Bai, Y | 1 |
| Wang, X | 1 |
| Wu, Y | 1 |
| Zhong, J | 1 |
| Wu, Q | 1 |
| Luo, Y | 1 |
| Shang, T | 1 |
| Shen, R | 1 |
| Xi, M | 1 |
| Sun, H | 1 |
| Tanaka, M | 1 |
| Toldi, J | 4 |
| Vécsei, L | 5 |
| Rodrigues, FB | 1 |
| Byrne, LM | 1 |
| Lowe, AJ | 1 |
| Tortelli, R | 1 |
| Heins, M | 1 |
| Flik, G | 1 |
| Johnson, EB | 1 |
| De Vita, E | 1 |
| Scahill, RI | 1 |
| Giorgini, F | 6 |
| Wild, EJ | 1 |
| Donley, DW | 2 |
| Realing, M | 1 |
| Gigley, JP | 2 |
| Fox, JH | 2 |
| Sathyasaikumar, KV | 4 |
| Breda, C | 2 |
| Schwarcz, R | 10 |
| Boros, FA | 1 |
| Klivényi, P | 3 |
| Amaral, M | 1 |
| Levy, C | 1 |
| Heyes, DJ | 1 |
| Lafite, P | 1 |
| Outeiro, TF | 1 |
| Leys, D | 1 |
| Scrutton, NS | 1 |
| Winkler, D | 2 |
| Beconi, M | 1 |
| Toledo-Sherman, LM | 2 |
| Prime, M | 1 |
| Ebneth, A | 1 |
| Dominguez, C | 2 |
| Muñoz-Sanjuan, I | 2 |
| Mazarei, G | 2 |
| Budac, DP | 1 |
| Lu, G | 1 |
| Adomat, H | 1 |
| Tomlinson Guns, ES | 1 |
| Möller, T | 3 |
| Leavitt, BR | 3 |
| Prime, ME | 1 |
| Mrzljak, L | 1 |
| Beconi, MG | 1 |
| Beresford, A | 1 |
| Brookfield, FA | 1 |
| Brown, CJ | 1 |
| Cardaun, I | 1 |
| Courtney, SM | 1 |
| Dijkman, U | 1 |
| Hamelin-Flegg, E | 1 |
| Johnson, PD | 1 |
| Kempf, V | 1 |
| Lyons, K | 1 |
| Matthews, K | 1 |
| Mitchell, WL | 1 |
| O'Connell, C | 1 |
| Pena, P | 1 |
| Powell, K | 1 |
| Rassoulpour, A | 1 |
| Reed, L | 1 |
| Reindl, W | 1 |
| Selvaratnam, S | 1 |
| Friley, WW | 1 |
| Weddell, DA | 1 |
| Went, NE | 1 |
| Wheelan, P | 1 |
| Winkler, C | 1 |
| Wityak, J | 1 |
| Yarnold, CJ | 1 |
| Yates, D | 1 |
| Olson, AR | 1 |
| Raisbeck, MF | 1 |
| Costantino, G | 1 |
| Vamos, E | 1 |
| Pardutz, A | 1 |
| Guidetti, P | 7 |
| Muchowski, PJ | 5 |
| Forrest, CM | 4 |
| Mackay, GM | 3 |
| Stoy, N | 3 |
| Spiden, SL | 1 |
| Taylor, R | 1 |
| Stone, TW | 4 |
| Darlington, LG | 4 |
| Stachowski, EK | 1 |
| Amori, L | 1 |
| Thevandavakkam, MA | 1 |
| Campesan, S | 1 |
| Green, EW | 1 |
| Kyriacou, CP | 1 |
| Zádori, D | 1 |
| Szalárdy, L | 1 |
| Fülöp, F | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Clark, CJ | 1 |
| Christofides, J | 1 |
| Egerton, M | 1 |
| Sapko, MT | 1 |
| Yu, P | 1 |
| Tagle, DA | 2 |
| Pellicciari, R | 1 |
| Bates, GP | 1 |
| Graham, RK | 1 |
| Hayden, MR | 1 |
| MacDonald, ME | 1 |
| Slow, EJ | 1 |
| Wheeler, VC | 1 |
| Woodman, B | 1 |
| Kwan, W | 1 |
| Zwilling, D | 1 |
| Wacker, JL | 1 |
| Hong, S | 1 |
| Tsai, LC | 1 |
| Cheah, CS | 1 |
| Guilarte, TR | 1 |
| Eastman, CL | 1 |
| Schapira, AH | 1 |
| Beal, MF | 4 |
| Harris, CA | 1 |
| Miranda, AF | 1 |
| Tanguay, JJ | 1 |
| Boegman, RJ | 1 |
| Beninger, RJ | 1 |
| Jhamandas, K | 1 |
| Leblhuber, F | 2 |
| Walli, J | 2 |
| Jellinger, K | 1 |
| Tilz, GP | 2 |
| Widner, B | 2 |
| Laccone, F | 1 |
| Fuchs, D | 2 |
| Demel, U | 1 |
| Reddy, PH | 1 |
| Matson, WR | 2 |
| Storey, E | 1 |
| Milbury, P | 1 |
| Ryan, EA | 1 |
| Ogawa, T | 1 |
| Bird, ED | 2 |
| Martin, JB | 1 |
| Pearson, SJ | 2 |
| Reynolds, GP | 2 |
| Swartz, KJ | 1 |
| Gamache, PH | 1 |
17 reviews available for kynurenine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
Topics: Aging; Animals; Huntington Disease; Kynurenine; Mammals; Models, Animal; Neurodegenerative Diseases | 2023 |
Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines.
Topics: Alzheimer Disease; Anti-Inflammatory Agents; Biomarkers; Cytokines; Humans; Huntington Disease; Infl | 2020 |
Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.
Topics: Animals; Disease Progression; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynu | 2019 |
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease.
Topics: Alzheimer Disease; Animals; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynure | 2015 |
New promises for manipulation of kynurenine pathway in cancer and neurological diseases.
Topics: Animals; Drug Delivery Systems; Drug Discovery; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3, | 2009 |
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.
Topics: Alzheimer Disease; Animals; Brain; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Dise | 2009 |
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; Huntington Disease; Kynurenine; Mice; Mutation; P | 2010 |
Neuroinflammation in Huntington's disease.
Topics: Calcium; Complement System Proteins; Encephalitis; Ferritins; Humans; Huntington Disease; Kynurenine | 2010 |
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Humans; Huntington Disease; Kynurenine; Kynu | 2010 |
Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.
Topics: Animals; Brain; Humans; Huntington Disease; Kynurenine; Stroke | 2012 |
Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders.
Topics: Animals; Brain Ischemia; Encephalitis; Humans; Huntington Disease; Kynurenine; Mitochondria | 2012 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Tryptophan metabolites and brain disorders.
Topics: AIDS Dementia Complex; Brain Diseases; Central Nervous System Diseases; Humans; Huntington Disease; | 2003 |
The use of toxins to elucidate neural function and disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Brain Diseases; Disease Models, Animal; Humans; | 1993 |
Huntington's disease and neurotoxins.
Topics: Animals; Brain; Humans; Huntington Disease; Kynurenine; Neurotoxins | 1992 |
27 other studies available for kynurenine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Anti-inflammatory effects of ellagic acid and vanillic acid against quinolinic acid-induced rat model of Huntington's disease by targeting IKK-NF-κB pathway.
Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Antioxidants; Caspase 3; Ellagic Acid; Hunt | 2022 |
Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.
Topics: Adult; Aged; Biomarkers; Chromatography, High Pressure Liquid; Cohort Studies; Female; Humans; Hunti | 2021 |
Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
Topics: Animals; Brain; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Huntingtin Protein; | 2021 |
Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
Topics: Aged; Animals; Brain; Disease Models, Animal; Enzyme Inhibitors; Female; Humans; Huntingtin Protein; | 2018 |
Structural basis of kynurenine 3-monooxygenase inhibition.
Topics: Arginine; Blood-Brain Barrier; Catalytic Domain; Crystallography, X-Ray; Cyclopropanes; Drug Design; | 2013 |
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
Topics: Animals; Cell Line; CHO Cells; Chromatography, Liquid; Cricetulus; Dogs; Drug Discovery; Enzyme Assa | 2013 |
Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
Topics: Aging; Animals; Brain; Cerebellum; Corpus Striatum; Female; Genotype; Huntington Disease; Indoleamin | 2013 |
Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
Topics: Animals; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Enzyme Inhibit | 2015 |
Huntingtons Disease Mice Infected with Toxoplasma gondii Demonstrate Early Kynurenine Pathway Activation, Altered CD8+ T-Cell Responses, and Premature Mortality.
Topics: Animals; Biomarkers; Brain; CD8-Positive T-Lymphocytes; Disease Models, Animal; Enzyme Activation; F | 2016 |
Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease.
Topics: Biomarkers; Female; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Hunti | 2010 |
Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
Topics: Age Factors; Animals; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Female; H | 2010 |
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Drosophila melanogaster; Huntington | 2011 |
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
Topics: Aged; Animals; Butyrates; Case-Control Studies; Cerebellum; Corpus Striatum; Frontal Lobe; Humans; H | 2003 |
Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
Topics: Adolescent; Adult; Aged; Aldehydes; Brain; Female; Humans; Huntington Disease; Kynurenine; Male; Mal | 2005 |
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease.
Topics: Animals; Brain Chemistry; Excitatory Amino Acid Agonists; Huntington Disease; Kainic Acid; Kynurenic | 2006 |
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di | 2006 |
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.
Topics: Animals; Disease Models, Animal; Gene Expression; Histone Deacetylases; Huntingtin Protein; Huntingt | 2008 |
Is 3-hydroxykynurenine an endogenous neurotoxin in Huntington's disease?
Topics: Humans; Huntington Disease; Kynurenine; Neurotoxins | 1993 |
Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Kynurenine; Papio; Probenecid; Rats; Re | 1996 |
Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Topics: Alanine; Animals; Anticonvulsants; Corpus Striatum; Dose-Response Relationship, Drug; Drug Synergism | 1998 |
Activated immune system in patients with Huntington's disease.
Topics: Adult; Antigens, CD; Complement C3; Female; Humans; Huntington Disease; Immunoglobulins; Kynurenine; | 1998 |
Degradation of tryptophan in neurodegenerative disorders.
Topics: Alzheimer Disease; Biomarkers; Humans; Huntington Disease; Intellectual Disability; Interleukin-2; K | 1999 |
Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
Topics: Aged; Animals; Disease Models, Animal; Humans; Huntingtin Protein; Huntington Disease; Kynurenine; M | 2000 |
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Energy Metabolism; Free Radicals; Humans; Huntington Disea | 1992 |
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
Topics: Aged; Alzheimer Disease; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Female; Humans; Huntingt | 1992 |
Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
Topics: Aged; Autopsy; Corpus Striatum; Female; Humans; Huntington Disease; Kynurenic Acid; Kynurenine; Male | 1990 |
Increased brain 3-hydroxykynurenine in Huntington's disease.
Topics: Brain Chemistry; Cerebral Cortex; Humans; Huntington Disease; Kynurenine; Tryptophan | 1989 |